RBC Capital Upgrades Pharmacyclics (PCYC) to Outperform
Tweet
Share
E-mailGet Alerts PCYC Hot Sheet
Price: $261.25 --0%
Rating Summary:
5 Buy, 17 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 1 | Down: 0 | New: 0
Rating Summary:
5 Buy, 17 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 1 | Down: 0 | New: 0
Join SI Premium – FREE
RBC Capital upgraded Pharmacyclics (NASDAQ: PCYC) from Sector Perform to Outperform, price target raised from $15 to $34.
For an analyst ratings summary and ratings history on Pharmacyclics click here. For more ratings news on Pharmacyclics click here.
Shares of Pharmacyclics closed at $24.48 yesterday.
For an analyst ratings summary and ratings history on Pharmacyclics click here. For more ratings news on Pharmacyclics click here.
Shares of Pharmacyclics closed at $24.48 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Upgrades Bystronic AG (BYS:SW) to Neutral
- BHP Billiton Ltd. (BHP:AU) (BHP) PT Raised to AUD67 at CLSA
- Huhtamaki Oyj (HUH1V:FH) PT Lowered to EUR35 at UBS
Create E-mail Alert Related Categories
Analyst PT Change, UpgradesRelated Entities
RBC CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
